Design Therapeutics, Inc. (DSGN) 

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Show less

Over the last 12 months, insiders at Design Therapeutics, Inc. have bought $0 and sold $3.49M worth of Design Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Design Therapeutics, Inc. have bought $20.73M and sold $1.88M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 17,809 shares for transaction amount of $66,606 was made by Schmid John P. (director) on 2024‑03‑25.